March 20, 2020
Ziphius Vaccines Announces Acceleration of mRNA Based Vaccine Development for COVID-19
ZIPHIUS Vaccines announced today that they have prioritized their resources to intensify the development of ZIP-1642, a vaccine against the novel coronavirus.
Ziphius Vaccines is therefore interacting with researchers at Ghent University who recently succeeded to produce an mRNA vaccine against Zika virus. This mRNA platform could also be applicable for the development of a COVID-19 vaccine.
“I am grateful to Ghent University, Professor Niek Sanders, and our team of researchers who are working hard to get this job done in these unusual times,” said Chris Cardon Chief Executive Officer at Ziphius. “All of us will do our outmost best and use our leading-edge technology to serve the community.”
Ziphius Vaccines also announced the appointment of Mathieu Ghadanfar as Business Development & Licensing Officer. Mathieu joins the Company from Novartis Pharma AG where he was most recently VP, Global Medical Affairs.
“The Ziphius vaccine consists of a combination of mRNA molecules, encoding multiple SARS-CoV-2 antigens, such as a form of the Spike (S) protein, which is an essential protein for host cell infection and has been evaluated as a vaccine antigen for multiple other corona viruses. By using a combination of antigens, Ziphius Vaccines hopes to elicit a broad and protective immune response.”
About Ziphius Vaccines
Ziphius Vaccines NV is a pre-clinical gene technology company that focuses on messenger RNA (mRNA) vaccines to create a new generation of transformative medicines for patients. Together with Ghent University, Ziphius Therapeutics is developing a portfolio of mRNA vaccines. To date, the Company has several therapeutic candidates in development in the fields of respiratory and endocrinological diseases, in addition to several prophylactic vaccines, including ZIP1642.
Headquartered in Oostkamp, Belgium, Ziphius Vaccines currently has strategic partnerships with experienced executives in the pharmaceutical industry that bring over 100 years of combined experience in drug development.